Researchers have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).  And in an early parallel study in humans, combining immunotherapy with dupilumab — an Interleukin-4 (IL-4) receptor-blocking antibody widely used for treating allergies and asthma — boosted patients’ immune systems, with one out of the six experiencing significant tumor reduction.